Infectivity-enhancing antibodies against SARS-CoV-2
Antibodies against the receptor binding domain of the spike protein of SARS-CoV-2 play an important role in preventing infection as neutralizing antibodies. However, antibodies that recognize a specific site on the N-terminal domain of the spike protein induce an open domain of receptor binding that increases the binding of ACE2 and enhances the infectivity of SARS-CoV-2. Furthermore, the presence of the infectivity-enhancing antibodies reduces the neutralizing activity of the neutralizing antibodies. Therefore, when considering the antibody response to SARS-CoV-2, it is necessary to consider not only neutralizing antibodies but also the balance between neutralizing and infectivity-enhancing antibodies. In this article, function and mechanism of infectivity-enhancing antibodies are introduced.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Uirusu - 71(2021), 2 vom: 28., Seite 169-174 |
| Sprache: |
Japanisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.05.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2222/jsv.71.169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357481836 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357481836 | ||
| 003 | DE-627 | ||
| 005 | 20231226072703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.2222/jsv.71.169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357481836 | ||
| 035 | |a (NLM)37245979 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 245 | 1 | 0 | |a Infectivity-enhancing antibodies against SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Antibodies against the receptor binding domain of the spike protein of SARS-CoV-2 play an important role in preventing infection as neutralizing antibodies. However, antibodies that recognize a specific site on the N-terminal domain of the spike protein induce an open domain of receptor binding that increases the binding of ACE2 and enhances the infectivity of SARS-CoV-2. Furthermore, the presence of the infectivity-enhancing antibodies reduces the neutralizing activity of the neutralizing antibodies. Therefore, when considering the antibody response to SARS-CoV-2, it is necessary to consider not only neutralizing antibodies but also the balance between neutralizing and infectivity-enhancing antibodies. In this article, function and mechanism of infectivity-enhancing antibodies are introduced | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 773 | 0 | 8 | |i Enthalten in |t Uirusu |d 1972 |g 71(2021), 2 vom: 28., Seite 169-174 |w (DE-627)NLM000245429 |x 0042-6857 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2021 |g number:2 |g day:28 |g pages:169-174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2222/jsv.71.169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2021 |e 2 |b 28 |h 169-174 | ||